Supernus Announces Second Quarter 2026 Financial Results
Supernus Pharmaceuticals delivered a 32% increase in total revenues to $219.1 million for Q2 2026, driven by strong sales growth of its CNS-focused products including Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. Collaboration revenue with Biogen on ZURZUVAE further boosted results. The company raised its full-year 2026 revenue guidance and announced an …